{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:30:43Z","timestamp":1794745843546,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novo Nordisk A\/S Fellowship"},{"name":"Oxfordshire Health Services Research Committee"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/15\/56\/31645 and FS\/SBSRF\/21\/31013"],"award-info":[{"award-number":["FS\/15\/56\/31645 and FS\/SBSRF\/21\/31013"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221805\/Z\/20\/Z"],"award-info":[{"award-number":["221805\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Slovak Grant Agency VEGA","award":["2\/0004\/23"],"award-info":[{"award-number":["2\/0004\/23"]}]},{"name":"Slovak Grant Agency APVV","award":["#21-0299"],"award-info":[{"award-number":["#21-0299"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    L-carnitine is critical for metabolism of some fatty acids therefore different carnitine species may play a role in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. Until recently, hepatic acetylcarnitine could not be quantified non-invasively. Now new technical developments in magnetic resonance spectroscopy (MRS) enable quantification of hepatic acetylcarnitine content in vivo. The aim of this study was to evaluate potential metabolic changes in healthy volunteers and patients with different stages of MASLD before and after a single injection of L-carnitine. This prospective study recruited 10 healthy volunteers and 17 patients (11 with low-risk MASLD, 6 with high-risk MASLD) who underwent cardiac and hepatic MRI and MRS for hepatic acetylcarnitine quantification at baseline and 2\u00a0h after injecting 50\u00a0mg\/kg body weight L-carnitine. Serum samples were obtained for biomarker measurement. A single injection of L-carnitine significantly elevated hepatic acetylcarnitine levels in healthy volunteers (\u0394\n                    <jats:sub>ACC<\/jats:sub>\n                    \u2009=\u20090.172,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.038) and low-risk MASLD (\u0394\n                    <jats:sub>ACC<\/jats:sub>\n                    \u2009=\u20091.677,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.043), but not in high-risk MASLD (\u0394\n                    <jats:sub>ACC<\/jats:sub>\n                    =-0.144,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.397). However, high-risk MASLD showed elevated hepatic acetylcarnitine at baseline (\u0394\n                    <jats:sub>ACC<\/jats:sub>\n                    \u2009=\u20090.58,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007), whereas variability in low-risk MASLD masked differences vs. healthy volunteers. At baseline, serum medium-chain carnitine species were higher in the high-risk MASLD group (0.88\u2009\u00b1\u20090.28\u00b5mol\/L,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) and low-risk MASLD group (0.77\u2009\u00b1\u20090.49\u00b5mol\/L,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03) compared to healthy volunteers (0.36\u2009\u00b1\u20090.23\u00b5mol\/L). We showed for the first time that acetylcarnitine can be evaluated in vivo in patients with different stages of MASLD. The divergent hepatic responses to L-carnitine suggest stage-dependent differences in hepatic metabolic response that may reflect disease severity, potentially arising from differences in metabolic flexibility, carnitine transport, mitochondrial function, or baseline saturation of hepatic acetylcarnitine. Further studies are needed to confirm whether hepatic or circulating acetylcarnitine levels could serve as early biomarkers of MASLD progression.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-54069-z","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:58:36Z","timestamp":1779443916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in hepatic L-carnitine levels in people with metabolic dysfunction-associated steatotic liver disease (MASLD) assessed by magnetic resonance techniques"],"prefix":"10.1038","volume":"16","author":[{"given":"Dragana","family":"Savic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pavlides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Skalsh\u00f8i","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sher May","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Valkovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc E.","family":"M\u00f3zes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"54069_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384. https:\/\/doi.org\/10.1002\/hep.28431 (2016).","journal-title":"Hepatology"},{"key":"54069_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl. J. Med. 363, 1341\u20131350. https:\/\/doi.org\/10.1056\/NEJMra0912063 (2010).","journal-title":"N Engl. J. Med."},{"key":"54069_CR3","doi-asserted-by":"publisher","unstructured":"Pei, K. et al. An overview of lipid metabolism and nonalcoholic fatty liver disease. Biomed Res Int 4020249, (2020). https:\/\/doi.org\/10.1155\/2020\/4020249 (2020).","DOI":"10.1155\/2020\/4020249"},{"key":"54069_CR4","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","volume":"1863","author":"N Longo","year":"2016","unstructured":"Longo, N., Frigeni, M. & Pasquali, M. Carnitine transport and fatty acid oxidation. Biochim. Biophys. Acta. 1863, 2422\u20132435. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.01.023 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"54069_CR5","doi-asserted-by":"publisher","unstructured":"Savic, D. et al. L-carnitine stimulates in vivo carbohydrate metabolism in the type 1 diabetic heart as demonstrated by hyperpolarized MRI. Metabolites 11 https:\/\/doi.org\/10.3390\/metabo11030191 (2021).","DOI":"10.3390\/metabo11030191"},{"key":"54069_CR6","doi-asserted-by":"publisher","first-page":"10663","DOI":"10.1038\/s41598-019-47216-2","volume":"9","author":"K Enooku","year":"2019","unstructured":"Enooku, K. et al. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Sci. Rep. 9, 10663. https:\/\/doi.org\/10.1038\/s41598-019-47216-2 (2019).","journal-title":"Sci. Rep."},{"key":"54069_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/ajg.2009.719","volume":"105","author":"M Malaguarnera","year":"2010","unstructured":"Malaguarnera, M. et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis\u2013a randomized and controlled clinical trial. Am. J. Gastroenterol. 105, 1338\u20131345. https:\/\/doi.org\/10.1038\/ajg.2009.719 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"54069_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/iub.1646","volume":"69","author":"MM Adeva-Andany","year":"2017","unstructured":"Adeva-Andany, M. M., Calvo-Castro, I., Fernandez-Fernandez, C. & Donapetry-Garcia, C. Pedre-Pineiro, A. M. Significance of l-carnitine for human health. IUBMB Life. 69, 578\u2013594. https:\/\/doi.org\/10.1002\/iub.1646 (2017).","journal-title":"IUBMB Life"},{"key":"54069_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/RLI.0000000000000355","volume":"52","author":"R Klepochova","year":"2017","unstructured":"Klepochova, R. et al. Detection and Alterations of Acetylcarnitine in Human Skeletal Muscles by 1H MRS at 7 T. Invest. Radiol. 52, 412\u2013418. https:\/\/doi.org\/10.1097\/RLI.0000000000000355 (2017).","journal-title":"Invest. Radiol."},{"key":"54069_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/mrm.26149","volume":"77","author":"L Lindeboom","year":"2017","unstructured":"Lindeboom, L. et al. Longitudinal relaxation time editing for acetylcarnitine detection with (1) H-MRS. Magn. Reson. Med. 77, 505\u2013510. https:\/\/doi.org\/10.1002\/mrm.26149 (2017).","journal-title":"Magn. Reson. Med."},{"key":"54069_CR11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/mrm.29544","volume":"89","author":"D Savic","year":"2023","unstructured":"Savic, D. et al. Detection and alterations of acetylcarnitine (AC) in human liver by (1) H MRS at 3T after supplementation with l-carnitine. Magn. Reson. Med. 89, 1314\u20131322. https:\/\/doi.org\/10.1002\/mrm.29544 (2023).","journal-title":"Magn. Reson. Med."},{"key":"54069_CR12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.numecd.2019.06.012","volume":"29","author":"ML Erickson","year":"2019","unstructured":"Erickson, M. L. et al. Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype. Nutr. Metab. Cardiovasc. Dis. 29, 1197\u20131204. https:\/\/doi.org\/10.1016\/j.numecd.2019.06.012 (2019).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"54069_CR13","doi-asserted-by":"publisher","first-page":"e2310771121","DOI":"10.1073\/pnas.2310771121","volume":"121","author":"AE Maloney","year":"2024","unstructured":"Maloney, A. E. et al. Large enrichments in fatty acid (2)H\/(1)H ratios distinguish respiration from aerobic fermentation in yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U S A. 121, e2310771121. https:\/\/doi.org\/10.1073\/pnas.2310771121 (2024).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"54069_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.media.2011.05.010","volume":"15","author":"C Lu","year":"2011","unstructured":"Lu, C. et al. An integrated approach to segmentation and nonrigid registration for application in image-guided pelvic radiotherapy. Med. Image Anal. 15, 772\u2013785. https:\/\/doi.org\/10.1016\/j.media.2011.05.010 (2011).","journal-title":"Med. Image Anal."},{"key":"54069_CR15","unstructured":"Chang, I. J., Lam, C. & Vockley, J. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency, (2000)."},{"key":"54069_CR16","doi-asserted-by":"publisher","unstructured":"Chistiakov, D. A., Sobenin, I. A., Revin, V. V., Orekhov, A. N. & Bobryshev, Y. V. Mitochondrial aging and age-related dysfunction of mitochondria. Biomed. Res. Int. 238463. https:\/\/doi.org\/10.1155\/2014\/238463 (2014).","DOI":"10.1155\/2014\/238463"},{"key":"54069_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-nutr-071715-050656","volume":"36","author":"C Koliaki","year":"2016","unstructured":"Koliaki, C. & Roden, M. Alterations of Mitochondrial Function and Insulin Sensitivity in Human Obesity and Diabetes Mellitus. Annu. Rev. Nutr. 36, 337\u2013367. https:\/\/doi.org\/10.1146\/annurev-nutr-071715-050656 (2016).","journal-title":"Annu. Rev. Nutr."},{"key":"54069_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/0148607109353440","volume":"34","author":"A Molfino","year":"2010","unstructured":"Molfino, A. et al. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. JPEN J. Parenter. Enter. Nutr. 34, 295\u2013299. https:\/\/doi.org\/10.1177\/0148607109353440 (2010).","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"54069_CR19","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbadis.2015.05.015","volume":"1852","author":"G Arguello","year":"2015","unstructured":"Arguello, G., Balboa, E., Arrese, M. & Zanlungo, S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim. Biophys. Acta. 1852, 1765\u20131778. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.015 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"54069_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.lfs.2018.04.022","volume":"203","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. Life Sci. 203, 291\u2013304. https:\/\/doi.org\/10.1016\/j.lfs.2018.04.022 (2018).","journal-title":"Life Sci."},{"key":"54069_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ajcn\/39.5.738","volume":"39","author":"DS Sachan","year":"1984","unstructured":"Sachan, D. S., Rhew, T. H. & Ruark, R. A. Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver. Am. J. Clin. Nutr. 39, 738\u2013744. https:\/\/doi.org\/10.1093\/ajcn\/39.5.738 (1984).","journal-title":"Am. J. Clin. Nutr."},{"key":"54069_CR22","unstructured":"Borum, P. R. in in Food Components to Enhance Performance: An Evaluation of Potential Performance-Enhancing Food Components for Operational Rations. (eds Marriott, B. M.) (National Academies, 1994)."},{"key":"54069_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/apt.13216","volume":"42","author":"ZG Jiang","year":"2015","unstructured":"Jiang, Z. G. et al. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment. Pharmacol. Ther. 42, 106\u2013116. https:\/\/doi.org\/10.1111\/apt.13216 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"54069_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/ATVBAHA.109.202275","volume":"30","author":"DC Chan","year":"2010","unstructured":"Chan, D. C. et al. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity. Arterioscler. Thromb. Vasc Biol. 30, 1043\u20131050. https:\/\/doi.org\/10.1161\/ATVBAHA.109.202275 (2010).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"54069_CR25","doi-asserted-by":"publisher","unstructured":"Ramadan, M. S., Russo, V., Nigro, G., Durante-Mangoni, E. & Zampino, R. Interplay between heart disease and metabolic steatosis: A contemporary perspective. J. Clin. Med. 10. https:\/\/doi.org\/10.3390\/jcm10081569 (2021).","DOI":"10.3390\/jcm10081569"},{"key":"54069_CR26","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.12998\/wjcc.v8.i20.4688","volume":"8","author":"U Arslan","year":"2020","unstructured":"Arslan, U. & Yenercag, M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J. Clin. Cases. 8, 4688\u20134699. https:\/\/doi.org\/10.12998\/wjcc.v8.i20.4688 (2020).","journal-title":"World J. Clin. Cases"},{"key":"54069_CR27","doi-asserted-by":"publisher","first-page":"e017371","DOI":"10.1161\/JAHA.120.017371","volume":"10","author":"G Styczynski","year":"2021","unstructured":"Styczynski, G. et al. Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis. J. Am. Heart Assoc. 10, e017371. https:\/\/doi.org\/10.1161\/JAHA.120.017371 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"54069_CR28","doi-asserted-by":"publisher","unstructured":"Carlsson, M. et al. Cardiac output and cardiac index measured with cardiovascular magnetic resonance in healthy subjects, elite athletes and patients with congestive heart failure. J. Cardiovasc. Magn. Reson. 14 https:\/\/doi.org\/10.1186\/1532-429X-14-51 (2012).","DOI":"10.1186\/1532-429X-14-51"},{"key":"54069_CR29","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1093\/eurheartj\/eht246","volume":"34","author":"S Moller","year":"2013","unstructured":"Moller, S. & Bernardi, M. Interactions of the heart and the liver. Eur. Heart J. 34, 2804\u20132811. https:\/\/doi.org\/10.1093\/eurheartj\/eht246 (2013).","journal-title":"Eur. Heart J."},{"key":"54069_CR30","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1053\/gast.1996.v111.pm8898644","volume":"111","author":"JC Garcia-Pagan","year":"1996","unstructured":"Garcia-Pagan, J. C. et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 111, 1300\u20131306. https:\/\/doi.org\/10.1053\/gast.1996.v111.pm8898644 (1996).","journal-title":"Gastroenterology"},{"key":"54069_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1532-429X-12-69","volume":"12","author":"SK Piechnik","year":"2010","unstructured":"Piechnik, S. K. et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J. Cardiovasc. Magn. Reson. 12, 69. https:\/\/doi.org\/10.1186\/1532-429X-12-69 (2010).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"54069_CR32","doi-asserted-by":"publisher","first-page":"e4030","DOI":"10.1002\/nbm.4030","volume":"32","author":"FE Mozes","year":"2019","unstructured":"Mozes, F. E. et al. Mapping tissue water T(1) in the liver using the MOLLI T(1) method in the presence of fat, iron and B(0) inhomogeneity. NMR Biomed. 32, e4030. https:\/\/doi.org\/10.1002\/nbm.4030 (2019).","journal-title":"NMR Biomed."},{"key":"54069_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","volume":"60","author":"R Banerjee","year":"2014","unstructured":"Banerjee, R. et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J. Hepatol. 60, 69\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2013.09.002 (2014).","journal-title":"J. Hepatol."},{"key":"54069_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/mrm.27728","volume":"82","author":"A Triay Bagur","year":"2019","unstructured":"Triay Bagur, A. et al. Magnitude-intrinsic water-fat ambiguity can be resolved with multipeak fat modeling and a multipoint search method. Magn. Reson. Med. 82, 460\u2013475. https:\/\/doi.org\/10.1002\/mrm.27728 (2019).","journal-title":"Magn. Reson. Med."},{"key":"54069_CR35","doi-asserted-by":"publisher","first-page":"e0185356","DOI":"10.1371\/journal.pone.0185356","volume":"12","author":"LAB Purvis","year":"2017","unstructured":"Purvis, L. A. B. et al. An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. PLoS One. 12, e0185356. https:\/\/doi.org\/10.1371\/journal.pone.0185356 (2017).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54069-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54069-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54069-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:09:04Z","timestamp":1785517744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54069-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54069"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54069-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DS, SMN, KT, TJ, GA, CH, SN, LH, LV, and FEM declare no competing interests. MSK is a full-time employee of Novo Nordisk A\/S. MP is a shareholder of Perspectum Ltd.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23397"}}